Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | ALDH1A3 | P47895 | 4/20 | 0.62 |
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | BAD | Q92934 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691332 | 0.87 | DYRK1A (0.60) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2129032 | 0.87 | ALDH1A1 (0.73) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL4726717 | 0.86 | ALDH1A1 (0.68) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL3498284 | 0.85 | ALDH1A1 (0.67) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2128899 | 0.83 | ALDH1A1 (0.72) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2127158 | 0.83 | APP (0.58) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL26665315 | 0.82 | HPGDS (0.58) | ALDH1A1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL2127570 | 0.82 | ALDH1A3 (0.65) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2126791 | 0.81 | HPGDS (0.52) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 | |
| SCHEMBL2126346 | 0.81 | HPGDS (0.66) | ALDH1A1KDM4EMEN1KMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | claimed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | claimed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | claimed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | claimed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | claimed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | claimed |
| US-20250283038-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-09-11 | — | — | US | disclosed |
| EP-4511027-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | Université Paris Cité (FR) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023203163-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | UNIVERSITE PARIS CITE (FR) | 2023-10-26 | — | — | WO | disclosed |
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399476-B2 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| EP-2129375-B1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2012-04-25 | — | — | EP | disclosed |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2129375-A1 | IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104278-A1 | IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2008-09-04 | — | — | WO | disclosed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | disclosed |
| EP-1964840-A1 | Imidazo[1,2-a]pyridines and their use as pharmaceuticals | sanofi-aventis (FR) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008029152-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250283038-A1 | COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS | CXCL10, IL2, IFNG | ALDH1A1 2221/4885KDM4E 3343/4885MEN1 3747/4885 |
| US-20100113412-A1 | IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS | NOS1, PTGIS, NOS2 | ALDH1A1 1286/4885KDM4E 879/4885MEN1 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.